Vorinostat Combined with DNMTi Epigenetically Controls the Proliferation of Lung Cancer Cells A 549

  title={Vorinostat Combined with DNMTi Epigenetically Controls the Proliferation of Lung Cancer Cells A 549},
  author={Hussein Sabit and Mostafa Fathy and Shimaa E. Abdel-Ghany and Osama A. M. Said and Mokhtar M. El-Zawahry},
Cancer is being considered one of the fatal diseasesin the global population. Lung cancer is one of the most common malignancies in males and inseveral countries also in females.In the presentstudy, we aimed at evaluating the role of different chemotherapeutic drugs belonging to three groups [Histone DeacetylaseInhibitors (HDACi), DNA Methyltransferase Inhibitors (DNMTi), and Alkylating Agents)]. Vorinostat, Carboplatin, Cyclophosphamide, Temozolomide, and Procaine were applied to A549 lung… 

Figures from this paper

Cancer Epigenetics: Shifting to More Deep Action

  • H. Sabit
  • Biology
    Novel Approaches in Cancer Study
  • 2019
Different mechanisms are involved in epigenetic-mediated carcinogenesis, each of them was extensively studied during the last four decades and provide unique and validated approach to treat different types of cancers.



Procaine Induces Epigenetic Changes in HCT116 Colon Cancer Cells

Data obtained indicated that different combinations had different effects in reducing or increasing the level of methylation, which might indicate the effectiveness of combining drugs in treating colon cancer cells.

Epigenetic synergy between decitabine and platinum derivatives

The results suggest that the combination of decitabine with platinum analogs shows epigenetic synergy that might be exploited in the treatment of different cancers.

Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells

Combined treatments with vor inostat promote the cytotoxicity of cisplatin and induce the expression of vorinostat-regulated acetyl proteins, eventually enhancing antitumor effects in SCLC cell lines.

Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor, Vorinostat.

It is suggested that improved understanding of epigenetic regulatory role of vorinostat and/or other HDACis will provide novel insights in improving utilization of this class of novel agents.

Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells.

Procaine is a DNA-demethylating agent that produces a 40% reduction in 5-methylcytosine DNA content as determined by high-performance capillary electrophoresis or total DNA enzyme digestion and is a promising candidate agent for future cancer therapies based on epigenetics.

Histone Methylation by Temozolomide; A Classic DNA Methylating Anticancer Drug.

Results showed that TMZ following conversion to a methylating cation, can methylate hist one H3 peptide and histone H3 protein, suggesting that TMZ exerts its anticancer activity not only through its interaction with DNA, but also through alterations of protein post-translational modifications.

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

Four major structural classes of HDAC inhibitors that are in clinical trials and different computer modeling tools available for their structural modifications are summarized as a guide to discover additional HDAC inhibitor-based therapies with greater therapeutic utility.

Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance

Results indicate that autophagy can switch from a proapoptotic signal to a prosurvival function driving acquired resistance, and the complexity of the design of combination strategies using modulators of autophagic and HDACi for the treatment of hematological malignancies is highlighted.

Tumor-specific histone signature and DNA methylation in multiple myeloma and leukemia cells.

A distinct histone signature in c-myc, Mcl-1, and ribosomal gene loci in MOLP8 MM and K562 leukemia cells is observed, when compared with lymphoblastoid cells.

The effect of common antineoplastic agents on induction of apoptosis in canine lymphoma and leukemia cell lines.

Canine lymphoma (CL-1, CLBL-1) and leukemia (GL- 1) cell lines are a useful tool for developing new and more effective treatment regimes for canine neoplasia.